BiotechTube

GM-CT-01 + 5-Fluorouracil

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer of the Bile Duct

Conditions

Cancer of the Bile Duct, Gallbladder Cancer

Trial Timeline

Sep 1, 2006 → Jun 1, 2009

NCT ID
NCT00386516

About GM-CT-01 + 5-Fluorouracil

GM-CT-01 + 5-Fluorouracil is a phase 2 stage product being developed by Galectin Therapeutics for Cancer of the Bile Duct. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00386516. Target conditions include Cancer of the Bile Duct, Gallbladder Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Cancer of the Bile Duct were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00386516Phase 2Withdrawn
NCT00054977Phase 1Completed

Competing Products

20 competing products in Cancer of the Bile Duct

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
E7389EisaiPhase 1
29
VeliparibAbbViePhase 2
27
AK-105AkesoPhase 1
29
XL820ExelixisPhase 1
26
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
27
LY3300054 + PrexasertibEli LillyPhase 1
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35